Search by PDG name  
   

 

BRAF  
    


    
      Official symbol:  BRAF
      Full name:  B-Raf proto-oncogene, serine/threonine kinase
      Location:  7q34
      Also known as:  BRAF1
      Entrez ID:  673
      Ensembl ID:  ENSG00000157764
      Summary:  This gene encodes a protein belonging to the RAF family of serine/threonine protein kinases. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which affects cell division, differentiation, and secretion. Mutations in this gene, most commonly the V600E mutation, are the most frequently identified cancer-causing mutations in melanoma, and have been identified in various other cancers as well, including non-Hodgkin lymphoma, colorectal cancer, thyroid carcinoma, non-small cell lung carcinoma, hairy cell leukemia and adenocarcinoma of lung. Mutations in this gene are also associated with cardiofaciocutaneous, Noonan, and Costello syndromes, which exhibit overlapping phenotypes. A pseudogene of this gene has been identified on the X chromosome. [provided by RefSeq, Aug 2017]

    

    
  Overall distribution
    
  Tissue specific distribution
    
 
  
 
   

    
  Overall distribution
    
  Tissue specific distribution
    
 
Gscore (Amp):  0.36  
Gscore (Del):  0.14  
 
Recurrently amplified in 2 cancer type(s)
Recurrently deleted in 1 cancer type(s)
   

    
  Overall distribution
    
  Tissue specific distribution
    
 
Mscore:  5.73  (Driver)
 
Recurrently mutated in 9 cancer type(s)
   

    
  Overall
    
  Tissue specific
    
 
Total fusion occurrence:  39  (Driver)
 
Fusions detected in 11 cancer type(s)
 
 

    
  Overall
    
  Tissue specific
    
   CRISPR: STRONGLY SELECTIVE 
 RNAi: STRONGLY SELECTIVE 
   
   

    
      Functional class:  Kinase (protein kinase)
      JensenLab PubMed score:  220.93  (Percentile rank: 82.80%)
      PubTator score:  4341.62  (Percentile rank: 99.33%)
      Target development/druggability level:  TclinThese targets have activities in DrugCentral (ie. approved drugs) with known mechanism of action.
      Tractability (small molecule):  Clinical PrecedenceTargets with drugs in phase II or above; Pre-clinical targets
      Tractability (antibody):  Predicted Tractable - High confidenceTargets located in the plasma membrane; Targets with GO cell component terms plasma membrane or secreted

    







Contact us | | Terms & Conditions.
Copyright © 2020 University of Pennsylvania. All Rights Reserved.